

Delta Hepatitis in Denver

WILLIAM G. RECTOR, Jr, MD, *Denver*; SUGANTHA GOVINDARAJAN, MD, *Downey, California*; and
KENT A. PENLEY and FRANKLYN N. JUDSON, MD, *Denver*

The prevalence of hepatitis D virus (HDV) infection in patients with hepatitis B virus (HBV) infection in the mid-United States is not well defined. We tested 65 patients seen between 1983 and 1986 with HBV infection in Denver for evidence of coexisting HDV infection. Five patients had anti-delta (δ) antibody. The prevalence of HDV infection was higher in patients with chronic hepatitis B (4/37) than in patients with acute hepatitis B (1/28). The prevalence of HDV infection in male homosexuals (3/32) was similar to reported figures, but the incidence of δ -infection in intravenous drug users in Denver was unusually low (1/16). In comparison to Los Angeles, New York, southern Italy, and Sweden, Denver appears to have a low incidence of HDV infection, which probably reflects its low prevalence in the drug-using population.

(Rector WG Jr, Govindarajan S, Penley KA, et al: Delta hepatitis in Denver. *West J Med* 1988 Jul; 149:40-42)

Ten years ago a new hepatitis virus, the delta (δ) agent, was described.¹ The δ -agent, now known as hepatitis D virus (HDV), is a small, defective ribonucleic acid virus that depends on the hepatitis B virus (HBV) for its own replication. The broad outlines of the epidemiology of HDV infection have been drawn, but significant gaps remain. In particular, there is little information about the prevalence of HDV infection in the mid-United States. We report the incidence and epidemiologic pattern of infection with the δ -agent in Denver, Colorado.

Patients and Methods

There were two sources of patients in this study. The first was 43 patients with hepatitis B infection seen in the Hepatitis Clinic of Denver General Hospital from about November 1985 to November 1986. The second was 22 homosexual men with chronic hepatitis B infection followed by the Disease Control Service at Denver General Hospital. These patients had participated in hepatitis B prevalence and incidence studies² and in a hepatitis B vaccine trial.³ Stored serum (-70°C) obtained between 1982 and 1986 was available on these patients.

Hepatitis B surface antigen (HBsAg) and immunoglobulin (Ig) M antibody to hepatitis B core antigen (anti-HBc) were measured by commercially available radioimmunoassays (Ausria II and Corab, respectively, Abbott Laboratories). IgG and IgM antibodies to the δ -agent were measured by solid-phase-capture radioimmunoassay.^{4,5}

Acute hepatitis B was diagnosed on the basis of a typical clinical picture with a pronounced increase in serum aminotransferase levels and evidence of anti-HBc IgM. All but one of the 28 patients with acute hepatitis B also had HBsAg. Chronic hepatitis was diagnosed as type B on the basis of the presence of HBsAg. Acute HDV infection was diagnosed on the basis of a low titer or the absence of IgG antibody to the δ -agent and the presence of a high titer of IgM antibody to hepatitis D. Chronic HDV infection was diagnosed on the

basis of a high titer of IgG antibody with a low titer of IgM antibody to the δ -agent.

Results

Of 65 patients with HBV infection, 5 had HDV superinfection (Table 1). The probable sources of hepatitis B and δ -infections were intravenous drug use (one patient), male homosexual activity (three patients), and inapparent (one patient). There were no overlapping risk factors. The intravenous drug user had acute hepatitis B and acute HDV infection. The other four patients had chronic hepatitis B and superimposed δ -infection. In two of these patients, both male homosexuals, HDV infection presented as acute hepatitis. Chronic HDV infection developed in one, resulting in chronic active hepatitis that progressed to biopsy-proved cirrhosis within two years. The other patient did not return for follow-up after his acute hepatitis subsided. The other two patients with chronic hepatitis B presented with coexisting chronic HDV infection. One was asymptomatic and had a serum aspartate aminotransferase concentration of less than twice normal. She refused liver biopsy. The second patient was mildly fatigued and had a serum aspartate aminotransferase concentration five times normal. He discontinued visits before further evaluation could be done.

Discussion

Hepatitis D virus is newly described.^{1,6} It is unique in being dependent on the HBV for its own replication and survival.⁶ Consequently, HDV infection only occurs in patients with coexisting HBV infection. This dual infection may take the form of acute HDV plus acute HBV infection, acute HDV infection superimposed on chronic HBV infection, or concurrent chronic HDV and chronic HBV infections. The addition of HDV infection to HBV infection increases the severity of hepatic inflammation.⁶ Patients with acute δ -infection superimposed on HBV infection (either acute or chronic) frequently go on to have fulminant hepatic

From the Department of Medicine, Division of Gastroenterology, Denver General Hospital (Dr Rector); the Rancho Los Amigos-University of Southern California Liver Unit (Dr Govindarajan), Downey, California; the Disease Control Service, Denver Department of Health and Hospitals (Mr Penley and Dr Judson); and the Department of Medicine (Dr Rector, Mr Penley, and Dr Judson), Division of Infectious Disease (Mr Penley and Dr Judson), University of Colorado Health Sciences Center, Denver.

Reprint requests to William G. Rector, Jr, MD, Department of Medicine, Box 4001, Denver General Hospital, 777 Bannock St, Denver, CO 80204-4507.

ABBREVIATIONS USED IN TEXT

anti-HBc = antibody to hepatitis B core antigen
 HBsAg = hepatitis B surface antigen
 HBV = hepatitis B virus
 HDV = hepatitis D virus
 Ig = immunoglobulin

failure.^{4,6,7} Patients with chronic HBV and δ -agent infections usually have chronic active hepatitis progressing to cirrhosis.⁶⁻⁹

A general outline of the worldwide epidemiology of HDV infection has taken shape in the decade since the first description of the δ -antigen and antibody system (Table 2). HDV infection complicates hepatitis B virus infection with a relatively high frequency in Italy and Scandinavia. A high incidence of HDV infection has been described among Indians in Venezuela and natives of Northwest Kenya. Infection with the δ -agent is relatively infrequent throughout Asia and in Australia.

In the United States, surveillance of patients with hepatitis B infection for HDV superinfection has mainly been done in large urban centers on the East and West coasts (Table 2). These areas, in particular California and New York, have had relatively high incidences of HDV infection.

In surveys of HBsAg-positive blood donors throughout the United States, δ -antibodies were found in 4% of subjects.¹⁰ The highest frequency (12%) was in San Jose, California, and the lowest in the south-central states (1%). These figures probably somewhat underestimate the frequency of δ -infection in this country. HDV infection usually produces severe hepatocellular injury, and acceptable volunteer blood donors have no history of liver disease. The present report, however, documents only a slightly higher incidence of HDV infection

TABLE 1.—Prevalence of Hepatitis D Virus Infection in Denver, 1982-1986

Patient Source	Hepatitis Clinic		Disease Control Service
Period of surveillance	1985-1986		1982-1986
Type of infection	Acute	Chronic	Chronic
Source of infection*			
Male homosexual	0/4	1/6	2/22
Intravenous drug use	1/12	0/4	0
No obvious source	0/10	1/4	0
Miscellaneous†	0/2	0/1	0
Totals	1/28	2/15	2/22

*The numbers indicate persons with the δ -agent/patients with hepatitis B.

†Transfusion (1) and birth in an endemic area (Vietnam, 1).

TABLE 2.—Epidemiology of δ -Infection

Location	Source	Period of Surveillance	Acute HBV Infection*	Chronic HBV Infection*
Italy	Rizzetto et al, 1979 ⁹	NS	...	48/227
	Raimondo et al, 1982 ¹¹	1979-1981	63/98†	41/63†
	Smedile et al, 1983 ¹²	1978-1981	99/687	238/1,314
	Arico et al, 1985 ¹³	1981-1984	...	112/2,487‡
	Maggiore et al, 1985 ¹⁴	1974-1982	...	13/102§
France	Rizzetto et al, 1980 ¹⁵	NS	...	1/92
Germany	Rizzetto et al, 1980 ¹⁵	NS	...	3/153
Poland	Rizzetto et al, 1980 ¹⁵	NS	...	1/50
Switzerland	Raimondo et al, 1982 ¹¹	1974-1981	6/17†	5/16†
Greece	Tassopoulos et al, 1986 ¹⁶	NS	...	4/167
Scandinavia	Rizzetto et al, 1980 ¹⁵	NS	...	9/19
	Hansson et al, 1982 ¹⁷	1970-1981	...	41/57
	Raimondo et al, 1982 ¹¹	1974-1981	3/7†	5/11‡
	Lindh et al, 1986 ¹⁸	NS	...	15/60
	Hess et al, 1986 ¹⁹	NS	...	2/44
Ireland	Raimondo et al, 1982 ¹¹	1974-1981	15/49†	...
Great Britain	Weller et al, 1983 ²⁰	NS	...	9/71
Taiwan	Rizzetto et al, 1980 ¹⁵	NS	...	4/53
Japan	Rizzetto et al, 1979 ¹⁰	NS	...	2/86
	Rizzetto et al, 1980 ¹⁵	NS	...	2/152
Australia	Rizzetto et al, 1980 ¹⁵	NS	...	1/21
Kenya	Thomas, 1985 ²¹	NS	...	NS (65%)
Venezuela	Hadler et al, 1984 ²²	1981-1982	...	47/83
USA, NJ	Rizzetto et al, 1979 ¹⁰	NS	...	8/25
NJ	Rizzetto et al, 1980 ¹⁵	NS	...	8/35
NY	Rizzetto et al, 1979 ¹⁰	NS	...	5/24
Mass	Jacobsen et al, 1985 ²³	1976-1984	6/114	15/110
Md	Rizzetto et al, 1980 ¹⁵	NS	...	0/81
Calif	Rizzetto et al, 1980 ¹⁵	NS	...	13/40
Calif	De Cock et al, 1986 ^{24,25}	1967-1985	17/358	45/200
Minn	Shiels et al, 1985 ²⁶	1969-1983	1/68	28/464
Colo	Present report	1983-1986	1/28	4/37

HBV = hepatitis B virus, NS = not stated

*The number with infection with the δ -agent versus the number with HBV infection.

†Intravenous drug users.

‡Asymptomatic carriers.

§Children.

||Male homosexuals.

in patients with clinically evident hepatitis B in Denver (5/65, 8%).

Antibodies to HDV frequently rise late in the course of acute HDV infection.⁶ Arguably, our estimate of the frequency of HDV coinfection in patients with acute hepatitis B could be falsely low. Such patients were typically seen first in primary care facilities, however, and had reached the peak of their illness or were in the convalescent phase when a serum specimen was drawn in the Hepatitis Clinic for HDV antibodies. Consequently, the number of false-negative diagnoses was probably minimal.

HDV infection appears to be transmitted most efficiently by the parenteral route.⁶ Most centers have reported the highest incidences in persons with hemophilia and in intravenous drug users.^{9,11,12,15,17,20} The HDV is infrequently transmitted by male homosexual activity. We found a 10% incidence of HDV infection in homosexual men with HBV infection. This is comparable to other reported figures.^{19,24} In contrast, the incidence of HDV infection in intravenous drug users in Denver (1/16) is considerably lower than that cited in most other reports.^{9,11,12,15,17,20} HDV coinfection rates in this group have been rising steadily in Sweden.¹⁷ The relative infrequency of HDV infection in Denver at present may indicate only that we are in the early stages of a developing epidemic. Continued surveillance will be necessary to define secular trends.

REFERENCES

1. Rizzetto M, Canese MG, Aricò S, et al: Immunofluorescence detection of a new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. *Gut* 1977; 18:997-1003
2. Schreeder MT, Thompson SE, Hadler SC, et al: Hepatitis B in homosexual men: Prevalence of infection and factors related to transmission. *J Infect Dis* 1982; 146:7-15
3. Francis PP, Hadler SC, Thompson SE, et al: The prevention of hepatitis B with vaccine: Report of the Centers for Disease Control multicenter efficacy trial among homosexual men. *Ann Intern Med* 1982; 87:362-366
4. Govindarajan S, Chin KP, Redeker AG, et al: Fulminant B viral hepatitis: Role of delta agent. *Gastroenterology* 1984; 86:1417-1420
5. Smedile A, Lavarini C, Crivelli O, et al: Radioimmunoassay detection of IgM antibodies to the HBV-associated delta (δ) antigen: Clinical significance in δ infection. *J Med Virol* 1982; 9:131-138
6. Rizzetto M: The delta agent. *Hepatology* 1983; 3:729-737
7. Smedile A, Farci P, Verme G, et al: Influence of delta infection on severity of hepatitis B. *Lancet* 1982; 2:945-947
8. Govindarajan S, Kanel GC, Peters RL: Prevalence of delta-antibody among chronic hepatitis B virus infected patients in the Los Angeles area: Its correlation with liver biopsy diagnosis. *Gastroenterology* 1983; 85:160-162
9. Rizzetto M, Shih JW, Gocke DJ, et al: Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. *Lancet* 1979; 2:986-990
10. Nath N, Mushahwar IK, Fang CT, et al: Antibodies to delta antigen in asymptomatic hepatitis B surface antigen-reactive blood donors in the United States and their association with other markers of hepatitis B virus. *Am J Epidemiol* 1985; 122:218-225
11. Raimondo G, Gallo L, Ponzetto A, et al: Multicenter study of prevalence of HBV-associated delta infection and liver disease in drug addicts. *Lancet* 1982; 1:249-251
12. Smedile A, Lavarini C, Farci P, et al: Epidemiologic patterns of infection with the hepatitis B virus-associated delta agent in Italy. *Am J Epidemiol* 1983; 117:223-229
13. Aricò S, Aragona M, Rizzetto M, et al: Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers. *Lancet* 1985; 2:356-358
14. Maggiore G, Hadchouel M, Sessa F, et al: A retrospective study of the role of delta agent infection in children with HBsAg-positive chronic hepatitis. *Hepatology* 1985; 5:7-9
15. Rizzetto M, Purcell RH, Gerin JL: Epidemiology of HBV-associated delta agent: Geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. *Lancet* 1980; 1:1215-1218
16. Tassopoulos NC, Sjogren MH, Ticehurst JR, et al: Significance of IgM antibody to hepatitis B core antigen in a Greek population with chronic hepatitis B virus infection. *Liver* 1986; 6:275-280
17. Hansson BG, Moestrup T, Widell A, et al: Infection with delta agent in Sweden: Introduction of a new hepatitis agent. *J Infect Dis* 1982; 146:472-478
18. Lindh G, Weiland O, Svedmyr A, et al: Long-term follow-up of 60 patients with chronic hepatitis B—I. Seroconversion in the hepatitis B e-system, frequency of delta infection and histologic outcome. *Liver* 1986; 6:7-12
19. Hess G, Bienzle U, Slusarczyk J, et al: Hepatitis B virus and delta infection in male homosexuals. *Liver* 1986; 6:13-16
20. Weller IVD, Karayiannis P, Lok ASF, et al: Significance of delta agent infection in chronic hepatitis B virus infection: A study in British carriers. *Gut* 1983; 24:1061-1063
21. Thomas HC: The delta agent comes of age. *Gut* 1985; 26:1-3
22. Hadler SC, de Monzon M, Ponzetto A, et al: Delta virus infection and severe hepatitis. *Ann Intern Med* 1984; 100:339-344
23. Jacobsen IM, Dienstag JL, Werner BG, et al: Epidemiology and clinical impact of hepatitis D virus (δ) infection. *Hepatology* 1985; 5:188-191
24. DeCock KM, Govindarajan S, Chen KP, et al: Delta hepatitis in the Los Angeles area: A report of 126 cases. *Ann Intern Med* 1986; 105:108-114
25. DeCock KM, Jones B, Govindarajan S, et al: Prevalence of hepatitis δ (delta) infection—A seroepidemiological study. *West J Med* 1988; 148:307-309
26. Shiels MT, Czaja AJ, Taswell HF, et al: Frequency and significance of delta antibody in acute and chronic hepatitis B. *Gastroenterology* 1985; 89:1230-1234